Related Experiment Video
Updated: Jul 18, 2026
06:16
Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model
Published on: April 19, 2024
Direct thrombin inhibitors - a survey of recent developments.
1Department of Molecular Genetics and Preparative Molecular Biology, Institute for Microbiology and Genetics, Grisebachstrasse 8, 37077, Goettingen, Germany. aschwie1@gwdg.de
Cellular and Molecular Life Sciences : CMLS
|November 15, 2006
Summary
Direct thrombin inhibitors show promise for preventing blood clots and heart attacks. Despite setbacks like Ximelagatran
Area of Science:
- Biochemistry
- Pharmacology
- Cardiovascular Medicine
Background:
- Thrombin, a key serine protease in coagulation and hemostasis, is implicated in thromboembolic diseases.
- Direct thrombin inhibitors offer potential for anticoagulant therapy in preventing thrombosis and myocardial infarction.
- Development of direct thrombin inhibitors has faced significant challenges, including toxicity concerns.
Purpose of the Study:
- To review the current status of direct thrombin inhibitors in clinical trials.
- To discuss recent research strategies for developing novel direct thrombin inhibitors.
Main Methods:
- Review of clinical trial data for direct thrombin inhibitors.
- Analysis of emerging research in the design of new anticoagulant agents.
Main Results:
- The development landscape for direct thrombin inhibitors is marked by both potential and significant hurdles.
- Withdrawal of Ximelagatran due to hepatotoxicity highlights safety challenges.
- Several drug candidates are currently undergoing clinical evaluation.
Conclusions:
- Despite past setbacks, direct thrombin inhibitors remain an important area of research for anticoagulation.
- Novel design strategies may overcome toxicity issues and lead to effective future anticoagulants.
- Continued investigation is crucial for advancing anticoagulant therapies.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...